A randomized trial of eribulin monotherapy versus eribulin plus anlotinib in patients with locally recurrent or metastatic breast cancer

BACKGROUND: Eribulin mesylate is a novel, nontaxane, microtubule dynamics inhibitor. In this study, we assessed the efficacy and safety of eribulin versus eribulin plus the oral small-molecule tyrosine kinase inhibitor anlotinib in patients with locally recurrent or metastatic breast cancer. PATIENT...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, B., Liu, L., Ran, J., Xie, N., Li, J., Xiao, H., Yang, X., Tian, C., Wu, H., Lu, J., Gao, J., Hu, X., Cao, M., Shui, Z., Hu, Z.-Y., Ouyang, Q.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10265607/
https://www.ncbi.nlm.nih.gov/pubmed/37285718
http://dx.doi.org/10.1016/j.esmoop.2023.101563

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10265607/
https://www.ncbi.nlm.nih.gov/pubmed/37285718
http://dx.doi.org/10.1016/j.esmoop.2023.101563

Ejemplares similares